Amarin Corp PLC (AMRN): Shareholders' Equity
$459.28M
As of 2025-12-31
$443.62M
As of 2026-06-30
-8.3%
3-year compound annual growth
-6.1%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $459.28M | -5.5% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $486.18M | -11.9% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $552.10M | -7.3% | 2026-03-02, Balance as of period end |
| 2022-12-31 | $595.33M | -10.8% | 2025-03-12, Balance as of period end |
| 2021-12-31 | $667.10M | +6.3% | 2024-02-29, Balance as of period end |
| 2020-12-31 | $627.50M | +3.2% | 2023-03-01, Balance as of period end |
| 2019-12-31 | $608.26M | +299.3% | 2022-03-01, Balance as of period end |
| 2018-12-31 | $152.33M | n/m | 2021-02-25, Balance as of period end |
| 2017-12-31 | -$65.10M | n/m | 2020-02-25, Balance as of period end |
| 2016-12-31 | -$9.06M | n/c | 2019-02-27, Balance as of period end |
| 2015-12-31 | -$127.55M | n/m | 2018-02-27, Balance as of period end |
| 2014-12-31 | -$88.45M | n/m | 2017-03-01, Balance as of period end |
| 2013-12-31 | -$33.86M | n/m | 2016-02-25, Balance as of period end |
| 2012-12-31 | -$4.00M | n/m | 2015-03-03, Balance as of period end |
| 2011-12-31 | -$5.96M | n/m | 2014-02-27, Balance as of period end |
| 2010-12-31 | -$202.37M | n/m | 2013-02-28, Balance as of period end |
| 2009-12-31 | $6.60M | n/a | 2012-02-29, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Amarin Corp PLC (AMRN) | 2025-12-31 | $459.28M | -5.5% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $327.19M | -39.2% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $1.02B | -3.4% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $130.34M | +41.5% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $37.21M | -47.5% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $32.61M | n/m |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $139.07M | +540.0% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $303.13M | -47.0% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $212.38M | -34.7% |
Compare AMRN, VNDA, IDYA, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗